1 / 20

Simple. - PowerPoint PPT Presentation

  • Uploaded on

THE SECTION ON Evidence Based Health Care OF THE NEW YORK ACADEMY OF MEDICINE. 2014 TEACH Workshop. Simple. Scientifically Informed Medical Practice and Learning. Suzana Alves da Silva, MD, MSc, PhD, FNYAM. Clinical Problems. P. I. C. O. What we know?.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Simple.' - opa

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript


Evidence Based Health Care


2014 TEACH Workshop


Scientifically Informed Medical Practice and Learning

Suzana Alves da Silva, MD, MSc, PhD, FNYAM

What we know

Clinical Problems





What we know?

Chatterji, M; Graham, M; Wyer, P. Mapping Cognitive Overlaps Between Practice-Based Learning and Improvement and Evidence-Based Medicine: An Operational Definition for Assessing Resident Physician Competence.2009

What is new

Frequency of outcome

Prediction of outcome


on outcome

What is new?

Silva, S and Wyer P. The Roadmap: a blueprint for evidence literacy within a Scientifically Informed Medical Practice and Learning Model. 2012

Likelihood issue on therapy
Likelihood issue on therapy

This scenario converges on an issue of the absolute probability of survival given maximal, evidence-based, interventions.

An elderly man is brought to the emergency room from a nursing home. He is febrile, hypotensive, anuric, minimally responsive. Medical and nursing staffs are preparing to implement an advanced protocol for sepsis care when the patient’s daughter arrives. The daughter wants to know “So, if you give him the most intense treatment, how likely is it that he will survive? It doesn’t make sense if he is likely to die anyway!”

Utility issue on prognosis
Utility issue on prognosis

This scenario involves a trade-off between risks versus benefits of sharing the results of a prognostic information.

A 40 year old woman is seeing her primary care physician. Her mother has recently been diagnosed with Alzheimer’s disease. She is concerned about the possibility that it could happen to her. The physician advises that there is a genetic test that could eliminate that likelihood. However, the woman expresses ambivalence, saying, “I am not sure I want to know.”

Performance issue on therapy
Performance issue on therapy

This scenario involves predicting the likelihood of benefit from a treatment if the predictor is present. It calls for information regarding the predictive performance of criteria such as a biomarker in modifying the probability of benefit from a therapeutic option.

A medical director of a health care organization is considering inclusion of BRCA1 within a panel of molecular biomarkers for optimization of individualized care of women with diagnosed breast cancer with respect to hormonal therapy, immune-therapy or chemo-therapy. His first question is what is the accuracy of BRCA1 mutation to predict that a women with cancer will in fact respond to a specific therapeutic regimen.

Levels of efficacy of Dx imaging tests

Phases of novel cardiac markers

diagnostic accuracy, sensitivity, and specificity associated with interpretation of the test.

whether the information produces change in the referring physician’s diagnostic thinking.

effect of the information on the patient management plan and on patient outcomes.

societal costs and benefits of a diagnostic imaging technology.






  • 1. Proof of concept—Do novel marker levels differ between subjects with and without outcome?

  • 2. Prospective validation—Does the novel marker predict development of future outcomes?

  • 4. Clinical utility—Does the novel risk marker change predicted risk sufficiently to change recommended therapy and to improve clinical outcomes?

  • 6. Cost-effectiveness—Does use of the marker justify additional costs of testing and treatment?

Fryback and Thornbury. 1991

Hlatky. AHA 2009

“My doctors estimated that I had an 87 percent risk of breast cancer and a 50 percent risk of ovarian cancer… Once I knew that this was my reality, I decided to be proactive and to minimize the risk as much as I could.”


HMOs being breast cancer and a 50 percent risk of ovarian pressured for the inclusion of BRCA mutation testing for screening of women with high risk of breast cancer.

Chief Medical Executive


Healthy Patient

Many patients with family history of cancer want to be tested for BRCA mutation. Many wonder about preventive surgery or chemotherapy on top of surveillance.

Many primary care physicians are ordering BRCA mutation testing to their patients or referring them for genetic counseling without knowing exactly what to do with it.


Brca1 for screening
BRCA1 for screening breast cancer and a 50 percent risk of ovarian

Brca1 for screening1
BRCA1 for screening breast cancer and a 50 percent risk of ovarian

Breast Cancer || Ovarian Cancer breast cancer and a 50 percent risk of ovarian

Women in general

Preventive surgery will drop the risk of cancer by ~ 90%

Little info about the effect of chemoprevention or close surveillance

Little info about impact on death

Source: 1. Senkus. European Society of Medical Oncology.2014. 2. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: U.S. Preventive Services Task Force Recommendation. 2013. 3. Berliner. National Society of Genetic Counselors 2013

Why this is so important1
Why this is so important? breast cancer and a 50 percent risk of ovarian

Recognition of questions of importance to patients, managers and policy makers in a fashion that facilitates the use of clinical research to inform the corresponding decisions.

Provide guidance regarding how to explore and interpret patient and stakeholder expressions of the concerns that will maximally inform decisions.

Categorization of clinical research designs in relationship to different types of clinical questions in a way that embraces the full spectrum of clinically relevant research.

Why this is so important2
Why this is so important? breast cancer and a 50 percent risk of ovarian

Thank you
Thank you! breast cancer and a 50 percent risk of ovarian

Therapy Utility breast cancer and a 50 percent risk of ovarian

Therapy Frequency

Prognosis Utility breast cancer and a 50 percent risk of ovarian

Prognosis Frequency